Skip to main content
Top
Published in: Journal of Urban Health 3/2011

01-06-2011

Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY

Authors: Carolyn Chu, Galina Umanski, Arthur Blank, Paul Meissner, Robert Grossberg, Peter A. Selwyn

Published in: Journal of Urban Health | Issue 3/2011

Login to get access

Abstract

Aging, HIV infection, and antiretroviral therapy have been associated with increasing rates of chronic comorbidities in patients with HIV. Urban minority populations in particular are affected by both the HIV/AIDS and chronic disease epidemics. Our objectives were to estimate the prevalence of and risk factors for hypertension, dyslipidemia, and diabetes among HIV-infected adults in the Bronx and describe comorbidity-related treatment outcomes. This was a cross-sectional study of 854 HIV-positive adults receiving care at 11 clinics which provide HIV primary care services; clinics were affiliated with a large urban academic medical center. Data on blood pressure (BP), cholesterol, and glycemic control were collected through standardized chart review of outpatient medical records. We found prevalence rates of 26%, 48%, and 13% for hypertension, dyslipidemia, and diabetes, respectively. Older age, obesity, family history, and current protease inhibitor use were consistently associated with comorbidity. Diabetes treatment goals were achieved less often than BP and lipid goals, and concurrent diabetes was a significant predictor for BP and lipid control. In conclusion, major cardiovascular-related comorbidities are prevalent among HIV-positive adults in the Bronx, especially older and obese individuals. Differences exist in comorbidity-related treatment outcomes, especially for patients with concurrent diabetes. Because cardiovascular risk is modifiable, effective treatment of related comorbidities may improve morbidity and mortality in HIV-infected patients.
Literature
1.
go back to reference Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003; 32(3): 298–302.PubMedCrossRef Justman JE, Benning L, Danoff A, et al. Protease inhibitor use and the incidence of diabetes mellitus in a large cohort of HIV-infected women. J Acquir Immune Defic Syndr. 2003; 32(3): 298–302.PubMedCrossRef
2.
go back to reference Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005; 165(10): 1179–84.PubMedCrossRef Brown TT, Cole SR, Li X, et al. Antiretroviral therapy and the prevalence and incidence of diabetes mellitus in the multicenter AIDS cohort study. Arch Intern Med. 2005; 165(10): 1179–84.PubMedCrossRef
3.
go back to reference Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV cohort study. HIV Med. 2006; 7(6): 404–10.PubMedCrossRef Glass TR, Ungsedhapand C, Wolbers M, et al. Prevalence of risk factors for cardiovascular disease in HIV-infected patients over time: the Swiss HIV cohort study. HIV Med. 2006; 7(6): 404–10.PubMedCrossRef
4.
go back to reference Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43(1): 27–34.PubMedCrossRef Palella FJ Jr, Baker RK, Moorman AC, et al. Mortality in the highly active antiretroviral therapy era: changing causes of death and disease in the HIV outpatient study. J Acquir Immune Defic Syndr. 2006; 43(1): 27–34.PubMedCrossRef
5.
go back to reference Adeyemi O, Vibhakar S, Max B. Are we meeting the American Diabetes Association goals for HIV-infected patients with diabetes mellitus? Clin Infect Dis. 2009; 49(5): 799–802.PubMedCrossRef Adeyemi O, Vibhakar S, Max B. Are we meeting the American Diabetes Association goals for HIV-infected patients with diabetes mellitus? Clin Infect Dis. 2009; 49(5): 799–802.PubMedCrossRef
6.
go back to reference Bury JE, Stroup JS, Stephens JR, Baker DL. Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus. Proc Bayl Univ Med Cent. 2007; 20(2): 118–23.PubMed Bury JE, Stroup JS, Stephens JR, Baker DL. Achieving American Diabetes Association goals in HIV-seropositive patients with diabetes mellitus. Proc Bayl Univ Med Cent. 2007; 20(2): 118–23.PubMed
7.
go back to reference Centers for Disease Control and Prevention. HIV prevalence estimates—United States, 2006. MMWR. 2008; 57(39): 1073–6. Centers for Disease Control and Prevention. HIV prevalence estimates—United States, 2006. MMWR. 2008; 57(39): 1073–6.
8.
go back to reference Link CL, McKinlay JB. Disparities in the prevalence of diabetes: is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis. 2009; 19(3): 288–92.PubMed Link CL, McKinlay JB. Disparities in the prevalence of diabetes: is it race/ethnicity or socioeconomic status? Results from the Boston Area Community Health (BACH) survey. Ethn Dis. 2009; 19(3): 288–92.PubMed
9.
go back to reference Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009; 6(11): 712–22.PubMedCrossRef Clark AM, DesMeules M, Luo W, Duncan AS, Wielgosz A. Socioeconomic status and cardiovascular disease: risks and implications for care. Nat Rev Cardiol. 2009; 6(11): 712–22.PubMedCrossRef
10.
go back to reference Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2009; 49(5): 651–81.PubMedCrossRef Aberg JA, Kaplan JE, Libman H, et al. Primary care guidelines for the management of persons infected with human immunodeficiency virus: 2009 update by the HIV medicine association of the infectious diseases society of America. Clin Infect Dis. 2009; 49(5): 651–81.PubMedCrossRef
11.
go back to reference Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560–72.PubMedCrossRef Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the joint national committee on prevention, detection, evaluation, and treatment of high blood pressure: the JNC 7 report. JAMA. 2003; 289(19): 2560–72.PubMedCrossRef
12.
go back to reference Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486–97. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA. 2001; 285(19):2486–97.
13.
go back to reference American Diabetes Association. Standards of medical care in diabetes—2008. Diab Care. 2008; 31(Suppl 1): S12–54.CrossRef American Diabetes Association. Standards of medical care in diabetes—2008. Diab Care. 2008; 31(Suppl 1): S12–54.CrossRef
14.
go back to reference Jung O, Bickel M, Ditting T, et al. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant. 2004; 19(9): 2250–8.PubMedCrossRef Jung O, Bickel M, Ditting T, et al. Hypertension in HIV-1-infected patients and its impact on renal and cardiovascular integrity. Nephrol Dial Transplant. 2004; 19(9): 2250–8.PubMedCrossRef
15.
go back to reference Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active antiretroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003; 22(12): 731–6.PubMedCrossRef Bergersen BM, Sandvik L, Dunlop O, Birkeland K, Bruun JN. Prevalence of hypertension in HIV-positive patients on highly active antiretroviral therapy (HAART) compared with HAART-naïve and HIV-negative controls: results from a Norwegian study of 721 patients. Eur J Clin Microbiol Infect Dis. 2003; 22(12): 731–6.PubMedCrossRef
16.
go back to reference Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDs. 2008; 22(12): 925–30.PubMedCrossRef Crum-Cianflone N, Tejidor R, Medina S, Barahona I, Ganesan A. Obesity among patients with HIV: the latest epidemic. AIDS Patient Care STDs. 2008; 22(12): 925–30.PubMedCrossRef
17.
go back to reference Korthuis PT, Asch SM, Anaya HD, et al. Lipid screening in HIV-infected veterans. J Acquir Immune Defic Syndr. 2004; 35(3): 253–60.PubMedCrossRef Korthuis PT, Asch SM, Anaya HD, et al. Lipid screening in HIV-infected veterans. J Acquir Immune Defic Syndr. 2004; 35(3): 253–60.PubMedCrossRef
18.
go back to reference Bell TJ, Tang S, Jamieson MJ. Evaluation of hypertension prevalence and blood pressure goal attainment using data from the 1999–2000 national health and nutrition examination survey (NHANES). Am J Hypertens. 2004; 17(5): S193.CrossRef Bell TJ, Tang S, Jamieson MJ. Evaluation of hypertension prevalence and blood pressure goal attainment using data from the 1999–2000 national health and nutrition examination survey (NHANES). Am J Hypertens. 2004; 17(5): S193.CrossRef
19.
go back to reference Pearson TA, Laurora L, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemia patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160(4): 459–67.PubMedCrossRef Pearson TA, Laurora L, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multicenter survey to evaluate the percentages of dyslipidemia patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch Intern Med. 2000; 160(4): 459–67.PubMedCrossRef
20.
go back to reference Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, Alexander CM. Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care settings. Diab Care. 2004; 27(3): 694–8.CrossRef Beaton SJ, Nag SS, Gunter MJ, Gleeson JM, Sajjan SS, Alexander CM. Adequacy of glycemic, lipid, and blood pressure management for patients with diabetes in a managed care settings. Diab Care. 2004; 27(3): 694–8.CrossRef
21.
go back to reference Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291(3): 335–42.PubMedCrossRef Saydah SH, Fradkin J, Cowie CC. Poor control of risk factors for vascular disease among adults with previously diagnosed diabetes. JAMA. 2004; 291(3): 335–42.PubMedCrossRef
22.
go back to reference Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. Top HIV Med. 2006; 14(5): 159–63.PubMed Justice AC. Prioritizing primary care in HIV: comorbidity, toxicity, and demography. Top HIV Med. 2006; 14(5): 159–63.PubMed
Metadata
Title
Comorbidity-Related Treatment Outcomes among HIV-Infected Adults in the Bronx, NY
Authors
Carolyn Chu
Galina Umanski
Arthur Blank
Paul Meissner
Robert Grossberg
Peter A. Selwyn
Publication date
01-06-2011
Publisher
Springer US
Published in
Journal of Urban Health / Issue 3/2011
Print ISSN: 1099-3460
Electronic ISSN: 1468-2869
DOI
https://doi.org/10.1007/s11524-010-9540-7

Other articles of this Issue 3/2011

Journal of Urban Health 3/2011 Go to the issue